MX2022013840A - Polipéptidos de unión a pd-1 canina y usos de los mismos. - Google Patents

Polipéptidos de unión a pd-1 canina y usos de los mismos.

Info

Publication number
MX2022013840A
MX2022013840A MX2022013840A MX2022013840A MX2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A MX 2022013840 A MX2022013840 A MX 2022013840A
Authority
MX
Mexico
Prior art keywords
canine
binding polypeptides
vhh
containing polypeptides
bind
Prior art date
Application number
MX2022013840A
Other languages
English (en)
Spanish (es)
Inventor
Rajay Pandit
Brendan P Eckelman
John C Timmer
Quinn Deveraux
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2022013840A publication Critical patent/MX2022013840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022013840A 2020-05-04 2021-05-03 Polipéptidos de unión a pd-1 canina y usos de los mismos. MX2022013840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019817P 2020-05-04 2020-05-04
PCT/US2021/030476 WO2021225961A1 (en) 2020-05-04 2021-05-03 Canine pd-1-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2022013840A true MX2022013840A (es) 2023-02-09

Family

ID=76076497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013840A MX2022013840A (es) 2020-05-04 2021-05-03 Polipéptidos de unión a pd-1 canina y usos de los mismos.

Country Status (10)

Country Link
US (1) US20230331846A1 (https=)
EP (1) EP4146696A1 (https=)
JP (1) JP2023524995A (https=)
KR (1) KR20230005955A (https=)
CN (1) CN115776990A (https=)
AU (1) AU2021266688A1 (https=)
BR (1) BR112022022352A2 (https=)
CA (1) CA3177921A1 (https=)
MX (1) MX2022013840A (https=)
WO (1) WO2021225961A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
JP2026508096A (ja) * 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体
CN120137035A (zh) * 2023-12-06 2025-06-13 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
CN106029697B (zh) * 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
KR102357893B1 (ko) * 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
CN107074952B (zh) * 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CN120623346A (zh) * 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
CN110194799B (zh) * 2019-06-03 2021-07-23 北京希诺谷生物科技有限公司 结合犬pd-1的抗犬pd-1抗体

Also Published As

Publication number Publication date
BR112022022352A2 (pt) 2023-01-10
CA3177921A1 (en) 2021-11-11
EP4146696A1 (en) 2023-03-15
AU2021266688A1 (en) 2022-12-08
CN115776990A (zh) 2023-03-10
JP2023524995A (ja) 2023-06-14
KR20230005955A (ko) 2023-01-10
US20230331846A1 (en) 2023-10-19
WO2021225961A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2021010827A (es) Materiales funcionales de origen vegetal.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
ZA202106602B (en) Claudin 6 antibodies and uses thereof
NZ795274A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
WO2019183359A8 (en) Methods and compositions for molecular authentication
PH12020551716A1 (en) Anti-ror antibody constructs
MX2019007021A (es) Anticuerpos il-11ra.
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
WO2020127377A9 (en) Bifunctional anti-pd-1/il-7 molecule
PH12021552970A1 (en) Tigit and pd-1/tigit-binding molecules.
EP4700161A3 (en) Direct-to-library methods, systems, and compositions
MX2026002648A (es) Polipeptidos de union al antigeno cd33 y sus usos
PH12020550556B1 (en) Novel combinations of defoliants
CR20230531A (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
WO2023091195A3 (en) Group14 composite
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2022011077A (es) Variantes de transglutaminasa.
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
MX2020013742A (es) Composición aglutinante de concreto diseñado que comprende componente mecano-químicamente modificado y su método de producción.
WO2023014908A8 (en) Lpar1 antagonists and uses thereof
SG10201806051XA (en) Compositions containing polymeric carbodiimide, epoxide and polyester-based polymers, their production and use
WO2022046669A3 (en) A nuclease and application thereof